Atlas Trials

A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL

Clinical trial NCT05036577 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05036577
Sponsor
Huashan Hospital
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Primary Central Nervous System Lymphoma
Start date
2021-10-10
Primary completion
2023-12-31
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.